Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

GSVA: gene set variation analysis for microarray and RNA-Seq data

Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440 · see citing works

Molecular signatures database (MSigDB) 3.0

Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111 · see citing works

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · see citing works

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · see citing works

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · see citing works

The EMBL-EBI search and sequence analysis tools APIs in 2019

Madeira, F., Park, Y. M., Lee, J., Buso, N., Gur, T., Madhusoodanan, N., Basutkar, P., Tivey, A. R. N., Potter, S. C., Finn, R. D., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz268 · Cited by 4,167 · see citing works

T cell exhaustion

Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · see citing works

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · see citing works

Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease

Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985 · see citing works

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · see citing works

Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms

Rőszer, T. (2015) · Mediators of Inflammation · doi:10.1155/2015/816460 · Cited by 1,762 · see citing works

TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes

Sanford, L. P., Ormsby, I., Groot, A. C. G.-D., Sariola, H., Friedman, R., Boivin, G. P., Cardell, E. L., & Doetschman, T. (1997) · Development · doi:10.1242/dev.124.13.2659 · Cited by 1,447 · see citing works

Latent TGF-β structure and activation

Shi, M., Zhu, J., Wang, R., Chen, X., Mi, L., Walz, T., & Springer, T. A. (2011) · Nature · doi:10.1038/nature10152 · Cited by 1,013 · see citing works

Transforming growth factor–β3 is required for secondary palate fusion

Proetzel, G., Pawlowski, S. A., Wiles, M. V., Yin, M., Boivin, G. P., Howles, P. N., Ding, J., Ferguson, M. W. J., & Doetschman, T. (1995) · Nature Genetics · doi:10.1038/ng1295-409 · Cited by 908 · see citing works

Hydrogen exchange mass spectrometry for the analysis of protein dynamics

Wales, T. E., & Engen, J. R. (2005) · Mass Spectrometry Reviews · doi:10.1002/mas.20064 · Cited by 864 · see citing works

Transforming Growth Factor-β Controls Development, Homeostasis, and Tolerance of T Cells by Regulatory T Cell-Dependent and -Independent Mechanisms

Li, M. O., Sanjabi, S., & Flavell, R. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.011 · Cited by 794 · see citing works

T Cell-Produced Transforming Growth Factor-β1 Controls T Cell Tolerance and Regulates Th1- and Th17-Cell Differentiation

Li, M. O., Wan, Y. Y., & Flavell, R. A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.014 · Cited by 728 · see citing works

The UCSC Xena platform for public and private cancer genomics data visualization and interpretationPreprint

Goldman, M., Craft, B., Hastie, M., Repečka, K., Kamath, A., McDade, F., Rogers, D., Brooks, A. N., Zhu, J., & Haussler, D. H. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/326470 · Cited by 604 · see citing works

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Lahn, M. M. F., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 558 · see citing works

The detection, correlation, and comparison of peptide precursor and product ions from data independent LC‐MS with data dependant LC‐MS/MS

Geromanos, S. J., Vissers, J. P. C., Silva, J. C., Dorschel, C. A., Li, G., Gorenstein, M. V., Bateman, R. H., & Langridge, J. (2009) · PROTEOMICS · doi:10.1002/pmic.200800562 · Cited by 499 · see citing works

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 494 · see citing works

Phase I study of GC1008 (fresolimumab): a human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma

Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090353 · Cited by 487 · see citing works

Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm

Lindsay, M. E., Schepers, D., Bolar, N. A., Doyle, J. J., Gallo, E. M., Fert‐Bober, J., Kempers, M. J. E., Fishman, E. K., Chen, Y., Myers, L. A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2349 · Cited by 482 · see citing works

GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3 + regulatory T cells

Tran, D. Q., Andersson, J., Wang, R., Ramsey, H. E., Unutmaz, D., & Shevach, E. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901944106 · Cited by 473 · see citing works

TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma

Oshimori, N., Oristian, D., & Fuchs, E. (2015) · Cell · doi:10.1016/j.cell.2015.01.043 · Cited by 471 · see citing works

Latent TGF-β-binding proteins

Robertson, I. B., Horiguchi, M., Zilberberg, L., Dabovic, B., Hadjiolova, K., & Rifkin, D. B. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.05.005 · Cited by 466 · see citing works

Regulatory mutations in transforming growth factor-?3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1

Beffagna, G., Occhi, G., Nava, A. K., Vitiello, L., Ditadi, A., Basso, C., Bauce, B., Carraro, G., Thiene, G., & Towbin, J. A. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.10.005 · Cited by 423 · see citing works

TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome

National Heart, L., Boileau, C., Guo, D.-C., Hanna, N., Regalado, E. S., Detaint, D., Gong, L., Varret, M., Prakash, S. K., Li, A. H., et al. (2012) · Nature Genetics · doi:10.1038/ng.2348 · Cited by 382 · see citing works

The Utility of Hydrogen/Deuterium Exchange Mass Spectrometry in Biopharmaceutical Comparability Studies

Houde, D. J., Berkowitz, S. A., & Engen, J. R. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22432 · Cited by 377 · see citing works

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice

Lau, J., Cheung, J., Navarro, A., Lianoglou, S., Haley, B., Tótpál, K., Sanders, L., Koeppen, H., Caplazi, P., McBride, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14572 · Cited by 365 · see citing works

The role of proteases in transforming growth factor-β activation

Jenkins, G. R. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.11.026 · Cited by 358 · see citing works

High-Speed and High-Resolution UPLC Separation at Zero Degrees Celsius

Wales, T. E., Fadgen, K. E., Gerhardt, G. C., & Engen, J. R. (2008) · Analytical Chemistry · doi:10.1021/ac8008862 · Cited by 353 · see citing works

The α _v β ₁ integrin plays a critical in vivo role in tissue fibrosis

Reed, N. I., Jo, H., Chen, C., Tsujino, K., Arnold, T. D., DeGrado, W. F., & Sheppard, D. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5094 · Cited by 311 · see citing works

Mutations in a TGF-β Ligand, TGFB3, Cause Syndromic Aortic Aneurysms and Dissections

Bertoli‐Avella, A. M., Gillis, E., Morisaki, H., Verhagen, J. M. A., de Graaf, B. M., van de Beek, G., Gallo, E. M., Kruithof, B. P. T., Venselaar, H., Myers, L. A., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.040 · Cited by 305 · see citing works

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Melisi, D., Garcia-Carbonero, R., Macarulla, T., Pezet, D., Deplanque, G., Fuchs, M., Trojan, J., Oettle, H., Kozloff, M., Cleverly, A., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0246-z · Cited by 294 · see citing works

Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors

Anderton, M. J., Mellor, H. R., Bell, A., Sadler, C., Pass, M., Powell, S., Steele, S. J., Roberts, R. R. A., & Heier, A. (2011) · Toxicologic Pathology · doi:10.1177/0192623311416259 · Cited by 284 · see citing works

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Brandes, A. A., Carpentier, A. F., Kesari, S., Sepulveda-Sanchez, J. M., Wheeler, H. R., Chinot, O., Cher, L., Steinbach, J. P., Capper, D., Specenier, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now009 · Cited by 273 · see citing works

Force interacts with macromolecular structure in activation of TGF-β

Dong, X., Zhao, B., Iacob, R. E., Zhu, J., Koksal, A. C., Lu, C., Engen, J. R., & Springer, T. A. (2017) · Nature · doi:10.1038/nature21035 · Cited by 273 · see citing works

A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody

Angal, S., King, D. J., Bodmer, M., Turner, A. V., Lawson, A. D. G., Roberts, G., Pedley, B. R., & Adair, J. R. (1993) · Molecular Immunology · doi:10.1016/0161-5890(93)90432-b · Cited by 245 · see citing works

Mice that lack activity of αvβ6- and αvβ8-integrins reproduce the abnormalities of Tgfb1 - and Tgfb3 -null mice

Aluwihare, P., Mu, Z., Zhao, Z., Yu, D., Weinreb, P. H., Horan, G. S. B., Violette, S. M., & Munger, J. S. (2008) · Journal of Cell Science · doi:10.1242/jcs.035246 · Cited by 224 · see citing works

Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors

Cassetta, L., & Kitamura, T. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00038 · Cited by 200 · see citing works

Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.

Meric-Bernstam, F., Sandhu, S. K., Hamid, O., Spreafico, A., Kasper, S., Dummer, R., Shimizu, T., Steeghs, N., Lewis, N., Talluto, C. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2507 · Cited by 190 · see citing works

GARP regulates the bioavailability and activation of TGFβ

Wang, R., Zhu, J., Dong, X., Shi, M., Lu, C., & Springer, T. A. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-12-1018 · Cited by 180 · see citing works

A Milieu Molecule for TGF-β Required for Microglia Function in the Nervous System

Qin, Y., Garrison, B. S., Ma, W., Wang, R., Jiang, A., Li, J., Mistry, M., Bronson, R. T., Santoro, D., Franco, C., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.027 · Cited by 180 · see citing works

Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo

Cuende, J., Liénart, S., Dedobbeleer, O., van der Woning, B., De Boeck, G., Stockis, J., Huygens, C., Colau, D., Somja, J., Delvenne, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1983 · Cited by 155 · see citing works

Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules

Teschendorff, A. E., Gómez, S., Arenas, À., El‐Ashry, D., Schmidt, M., Gehrmann, M. C., & Caldas, C. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-604 · Cited by 152 · see citing works

Function-blocking Integrin αvβ6 Monoclonal Antibodies

Weinreb, P. H., Simon, K. J., Rayhorn, P., Yang, W. J., Leone, D. R., Dolinski, B. M., Pearse, B. R., Yokota, Y., Kawakatsu, H., Atakilit, A., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312103200 · Cited by 149 · see citing works

Myeloid-Derived Suppressor Cells Are Controlled by Regulatory T Cells via TGF-β during Murine Colitis

Lee, C., Kwak, Y., Yang, T., Han, J. H., Park, S., Ye, M. B., Lee, W., Sim, K.-Y., Kang, J., Kim, Y., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.062 · Cited by 142 · see citing works

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A. M., Carlino, M. S., Grob, J., Kim, T. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.108 · Cited by 132 · see citing works

Integrin αvβ8–expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells

Takasaka, N., Seed, R. I., Cormier, A., Bondesson, A. J., Lou, J., Elattma, A., Ito, S., Yanagisawa, H., Hashimoto, M., Ma, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122591 · Cited by 119 · see citing works

Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8

Stockis, J., Liénart, S., Colau, D., Collignon, A., Nishimura, S. L., Sheppard, D., Coulie, P. G., & Lucas, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710680114 · Cited by 111 · see citing works

Transforming growth factor beta signaling in adult cardiovascular diseases and repair

Doetschman, T., Barnett, J. V., Runyan, R. B., Camenisch, T. D., Heimark, R. L., Granzier, H. L. M., Conway, S. J., & Azhar, M. (2011) · Cell and Tissue Research · doi:10.1007/s00441-011-1241-3 · Cited by 103 · see citing works

Glioblastoma Angiogenesis and Tumor Cell Invasiveness Are Differentially Regulated by β8 Integrin

Tchaicha, J. H., Reyes, S. B., Shin, J., Hossain, M. G., Lang, F. F., & McCarty, J. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0991 · Cited by 95 · see citing works

Selective Targeting of TGF-β Activation to Treat Fibroinflammatory Airway Disease

Minagawa, S., Lou, J., Seed, R. I., Cormier, A., Wu, S., Cheng, Y., Murray, L., Tsui, P., Connor, J., Herbst, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008074 · Cited by 90 · see citing works

Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment

Gonzàlez-Juncà, A., Driscoll, K. E., Pellicciotta, I., Du, S., Lo, C. H., Roy, R., Parry, R., Tenvooren, I., Marquez, D. M., Spitzer, M. H., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0310 · Cited by 89 · see citing works

Antibody Targeting of TGF-β in Cancer Patients

Lonning, S. M., Mannick, J. B., & McPherson, J. M. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111798808392 · Cited by 84 · see citing works

Defining a therapeutic window for the novel TGF ‐β inhibitor LY 2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

Gueorguieva, I., Cleverly, A., Stauber, A. J., Pillay, N. S., Rodon, J. A., Miles, C., Yingling, J. M., & Lahn, M. M. F. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12256 · Cited by 77 · see citing works

Thoracic aortic-aneurysm and dissection in association with significant mitral valve disease caused by mutations in TGFB2

Renard, M., Callewaert, B. L., Malfait, F., Campens, L., Sharif, S., Campo, M. D., Valenzuela, I., McWilliam, C. A., Coucke, P. J., Paepe, A. D., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.09.029 · Cited by 68 · see citing works

Nuclear Factor I-C Links Platelet-Derived Growth Factor and Transforming Growth Factor β1 Signaling to Skin Wound Healing Progression

Plasari, G., Calabrese, A., Dusserre, Y., Gronostajski, R. M., Mcnair, A., Michalik, L., & Mermod, N. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01921-08 · Cited by 62 · see citing works

TGFβ signaling and congenital heart disease: Insights from mouse studies

Arthur, H. M., & Bamforth, S. D. (2011) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.20794 · Cited by 51 · see citing works

Overexpression of human transforming growth factor-β1 using a recombinant CHO cell expression system

Zou, Z., & Sun, P. D. (2004) · Protein Expression and Purification · doi:10.1016/j.pep.2003.06.001 · Cited by 48 · see citing works

Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms

Bedinger, D., Lao, L., Khan, S., Lee, S., Takeuchi, T., & Mirza, A. M. (2016) · mAbs · doi:10.1080/19420862.2015.1115166 · Cited by 42 · see citing works

TGF-β signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond syndrome

Joyce, C. E., Saadatpour, A., Ruiz‐Gutierrez, M., Bölükbaşı, Ö. V., Jiang, L., Thomas, D. D., Young, S., Hofmann, I., Sieff, C. A., Myers, K. C., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125375 · Cited by 34 · see citing works

Nonclinical Safety Evaluation of a Transforming Growth Factor β Receptor I Kinase Inhibitor in Fischer 344 Rats and Beagle Dogs

Stauber, A. J. (2014) · Journal of Clinical Toxicology · doi:10.4172/2161-0495.196 · Cited by 31 · see citing works

NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.

Siefker-Radtke, A. O., Fishman, M., Balar, A. V., Grignani, G., Diab, A. K., Gao, J., Tagliaferri, M. A., Hannah, A. L., Karski, E. E., Zalevsky, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.388 · Cited by 22 · see citing works

Transforming Growth Factor Beta-2 Mutations in Barlow’s Disease and Aortic Dilatation

Disha, K., Schulz, S., Kuntze, T., & Girdauskas, E. (2017) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2017.01.103 · Cited by 8 · see citing works

ScholarRock/Martin-et-al-STM-2020 v0.1

Martin, C. J., Datta, A., Littlefield, C., Kalra, A., Chapron, C., Wawersik, S., Dagbay, K. B., Brueckner, C., Nikiforov, A., Danehy, F. T., et al. (2020) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.3698168 · Cited by 1 · see citing works

TGF-β signaling in health, disease and therapeutics

Deng, Z., Fan, T. T., Chu, X., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,270 · see citing works

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works

Immunotherapy: Reshape the Tumor Immune Microenvironment

Bingzhe, L. V., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 489 · see citing works

Resistance Mechanisms to Anti-PD Cancer Immunotherapy

Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468 · see citing works

Novel therapies emerging in oncology to target the TGF‐β pathway

Kim, B.-G., Malek, E., Choi, S. H., Ignatz-Hoover, J. J., & Driscoll, J. J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01053-x · Cited by 453 · see citing works

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors

Lei, Q., Wang, D., Sun, K., Wang, L., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00672 · Cited by 414 · see citing works

Targeting TGFβ signal transduction for cancer therapy

Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413 · see citing works

Overcoming TGFβ-mediated immune evasion in cancer

Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377 · see citing works

TGF ‐β as a driver of fibrosis: physiological roles and therapeutic opportunities

Budi, E. H., Schaub, J. R., Decaris, M. L., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 300 · see citing works

Neutrophil extracellular traps promote metastasis in gastric cancer patients with postoperative abdominal infectious complications

Xia, X., Zhang, Z., Zhu, C., Ni, B., Wang, S., Yang, S., Yu, F., Zhao, E., Li, Q., & Zhao, G. (2022) · Nature Communications · doi:10.1038/s41467-022-28492-5 · Cited by 219 · see citing works

The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology

Wienke, J., Dierselhuis, M. P., Tytgat, G. A. M., Künkele, A., Nierkens, S., & Molenaar, J. J. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.014 · Cited by 216 · see citing works

Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment

Desbois, M., & Wang, Y. (2021) · Immunological Reviews · doi:10.1111/imr.12982 · Cited by 215 · see citing works

Designing Cancer Immunotherapies That Engage T Cells and NK Cells

Kyrysyuk, O., & Wucherpfennig, K. W. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-044122 · Cited by 215 · see citing works

TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts

Grauel, A. L., Nguyen, B., Ruddy, D., Laszewski, T., Schwartz, S., Chang, J., Chen, J., Piquet, M., Pelletier, M., Yan, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19920-5 · Cited by 211 · see citing works

TGF-β Signaling and Resistance to Cancer Therapy

Zhang, M., Zhang, Y. Y., Chen, Y., Wang, J., Wang, Q., & Lu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.786728 · Cited by 199 · see citing works

KRAS drives immune evasion in a genetic model of pancreatic cancer

Ischenko, I., D’Amico, S., Rao, M., Li, J., Hayman, M. J., Powers, S., Petrenko, O., & Reich, N. C. (2021) · Nature Communications · doi:10.1038/s41467-021-21736-w · Cited by 184 · see citing works

Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment

Gulley, J. L., Schlom, J., Barcellos‐Hoff, M. H., Wang, X., Seoane, J., Audhuy, F., Lan, Y., Dussault, I., & Moustakas, A. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13146 · Cited by 178 · see citing works

TGF-beta signal transduction: biology, function and therapy for diseases

Tie, Y., Tang, F., Peng, D., Zhang, Y., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00109-9 · Cited by 178 · see citing works

Transforming Growth Factor-β: A Multifunctional Regulator of Cancer Immunity

Xue, V. W., Chung, J. Y., Córdoba, C. A. G., Cheung, A. H. K., Kang, W., Lam, E. W. ‐., Leung, K. T., To, K., Lan, H. Y., & Tang, P. M. (2020) · Cancers · doi:10.3390/cancers12113099 · Cited by 149 · see citing works

Mechano-therapeutics: Targeting Mechanical Signaling in Fibrosis and Tumor Stroma

Tschumperlin, D. J., & Lagares, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107575 · Cited by 142 · see citing works

TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective

Nixon, B. G., Gao, S., Wang, X., & Li, M. O. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00796-z · Cited by 138 · see citing works

TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesis

Sun, T., Huang, Z., Liang, W.-C., Yin, J., Lin, W. Y., Wu, J., Vernes, J.-M., Lutman, J., Caplazi, P., Jeet, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0407 · Cited by 134 · see citing works

Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance

Bell, H. N., & Zou, W. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-024752 · Cited by 133 · see citing works

Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers

Li, Y., Zhao, B., Peng, J., Tang, H., Wang, S., Peng, S., Ye, F., Wang, J., Ouyang, K., Li, J., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101042 · Cited by 131 · see citing works

Targeting immunosuppression by TGF-β1 for cancer immunotherapy

de Streel, G., & Lucas, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114697 · Cited by 129 · see citing works

Reactive oxygen species-sensitive polymeric nanocarriers for synergistic cancer therapy

Cao, Z., Li, D., Wang, J., & Yang, X. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.023 · Cited by 118 · see citing works

Roles of TGF-β signaling pathway in tumor microenvirionment and cancer therapy

Zhao, H., Wei, J., & Sun, J. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107101 · Cited by 117 · see citing works

Synergistic checkpoint-blockade and radiotherapy–radiodynamic therapy via an immunomodulatory nanoscale metal–organic framework

Ni, K., Xu, Z., Culbert, A. A., Luo, T., Guo, N., Yang, K., Pearson, E. A., Preusser, B., Wu, T., Rivière, P. J. L., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00846-w · Cited by 113 · see citing works

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

Martínez-Usatorre, A., Kadioglu, E., Boivin, G., Cianciaruso, C., Guichard, A., Torchia, B., Zangger, N., Nassiri, S., Keklikoglou, I., Schmittnaegel, M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1616 · Cited by 103 · see citing works

Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors

Castiglioni, A., Yang, Y., Williams, K., Gogineni, A., Lane, R. S., Wang, A. W., Shyer, J. A., Zhang, Z., Mittman, S., Gutierrez, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40398-4 · Cited by 99 · see citing works

Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy

Krishnamoorthy, M., Gerhardt, L., & Vareki, S. M. (2021) · Cells · doi:10.3390/cells10051170 · Cited by 97 · see citing works

Immunotherapy for advanced hepatocellular carcinoma, where are we?

Li, Z., Ding, J., Li, H., Wang, Z., & Wu, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188441 · Cited by 95 · see citing works

The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?

Gonzalez‐Sanchez, E., Vaquero, J., Fernández‐Barrena, M. G., Lasarte, J. J., Avila, M. A., Sarobe, P., Reig, M., Calvo, M., & Fabregat, I. (2021) · Cancers · doi:10.3390/cancers13133248 · Cited by 95 · see citing works

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy

Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 94 · see citing works

TGFβ-Directed Therapeutics: 2020

Teicher, B. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107666 · Cited by 92 · see citing works

Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy

Zhou, M., Wang, J., Pan, J., Wang, H., Huang, L., Hou, B., Lai, Y., Wang, F., Guan, Q., Wang, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39035-x · Cited by 91 · see citing works

TGF-β signaling networks in the tumor microenvironment

Chan, M. K.-K., Chung, J. Y.-F., Tang, P. C.-T., Chan, A. S.-W., Ho, J. Y.-Y., Lin, T. P.-T., Chen, J., Leung, K.-T., To, K.-F., Lan, H.-Y., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215925 · Cited by 90 · see citing works

Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects

Cao, Z., Quazi, S., Arora, S., Osellame, L. D., Burvenich, I. J. G., Janes, P. W., & Scott, A. M. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-024-01099-2 · Cited by 85 · see citing works

TGF-β Signaling in Metastatic Colorectal Cancer (mCRC): From Underlying Mechanism to Potential Applications in Clinical Development

Li, X.-S., Wu, Y., & Tian, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214436 · Cited by 82 · see citing works

The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial

Metropulos, A. E., Munshi, H. G., & Principe, D. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104380 · Cited by 81 · see citing works

Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities

Caramelo, B., Zagorac, S., Corral, S., Marqués, M., & Real, F. X. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.02.011 · Cited by 78 · see citing works

Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses

Odunsi, K. O., Qian, F., Lugade, A. A., Yu, H., Geller, M. A., Fling, S. P., Kaiser, J. C., Lacroix, A. M., D’Amico, L., Ramchurren, N., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abg8402 · Cited by 77 · see citing works

News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors

Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 75 · see citing works

Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression

van den Bulk, J., de Miranda, N. F. C. C., & ten Dijke, P. (2021) · Clinical Science · doi:10.1042/cs20201236 · Cited by 75 · see citing works

Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade

Malenica, I., Adam, J., Corgnac, S., Mezquita, L., Auclin, É., Damei, I., Grynszpan, L., Gros, G., de Montpréville, V., Planchard, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25322-y · Cited by 72 · see citing works

Revisiting the role of cancer-associated fibroblasts in tumor microenvironment

Lan, X., Li, W., Zhao, K., Wang, J., Li, S., & Hai, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1582532 · Cited by 72 · see citing works

The role of LTBPs in TGF beta signaling

Rifkin, D. B., Sachan, N., Singh, K., Sauber, E., Tellides, G., & Ramirez, F. (2021) · Developmental Dynamics · doi:10.1002/dvdy.331 · Cited by 68 · see citing works

Cancer immune exclusion: breaking the barricade for a successful immunotherapy

Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, R. I. C., & Schillaci, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135456 · Cited by 66 · see citing works

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 66 · see citing works

Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases

Shi, N., Wang, Z., Zhu, H., Liu, W., Zhao, M., Jiang, X., Zhao, J., Ren, C., Zhang, Y., & Luo, L. (2022) · Immunologic Research · doi:10.1007/s12026-022-09267-y · Cited by 65 · see citing works

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy

Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 63 · see citing works

Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy

Tschernia, N. P., & Gulley, J. L. (2022) · BioDrugs · doi:10.1007/s40259-022-00521-1 · Cited by 61 · see citing works

Context-dependent TGFβ family signalling in cell fate regulation

Richardson, L., Wilcockson, S. G., Guglielmi, L., & Hill, C. S. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00638-3 · Cited by 61 · see citing works

Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer

Busenhart, P., Montalban‐Arques, A., Katkeviciutė, E., Morsy, Y., Passen, C. V., Hering, L., Atrott, K., Lang, S., Garzon, J. F. G., Naschberger, E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003465 · Cited by 58 · see citing works

CAF-immune cell crosstalk and its impact in immunotherapy

Maia, A. R. R., Schöllhorn, A., Schuhmacher, J., & Gouttefangeas, C. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00977-x · Cited by 57 · see citing works

TGF-β signaling pathway: Therapeutic targeting and potential for anti-cancer immunity

Ali, S., Rehman, M. U., Yatoo, A. M., Arafah, A. M., Khan, A., Rashid, S., Majid, S., Ali, A., & Ali, M. N. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175678 · Cited by 57 · see citing works

Exploring TGF-β Signaling in Cancer Progression: Prospects and Therapeutic Strategies

Sheikh, K., Amjad, M., Irfan, M., Anjum, S., Majeed, T., Riaz, M. U., Jassim, A. Y., Sharif, E., & Ibrahim, W. N. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s493643 · Cited by 57 · see citing works

Pro-tumor γδ T Cells in Human Cancer: Polarization, Mechanisms of Action, and Implications for Therapy

Chabab, G., Barjon, C., Bonnefoy, N., & Lafont, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02186 · Cited by 55 · see citing works

Tumor Microenvironment and Hydrogel-Based 3D Cancer Models for In Vitro Testing Immunotherapies

Vitale, C., Marzagalli, M., Scaglione, S., Dondero, A., Bottino, C., & Castriconi, R. (2022) · Cancers · doi:10.3390/cancers14041013 · Cited by 54 · see citing works

Long Noncoding RNAs Control the Modulation of Immune Checkpoint Molecules in Cancer

Xu, S., Wang, Q., Kang, Y., Liu, J., Yin, Y., Liu, L., Wu, H., Li, S., Sui, S., Shen, M., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0696 · Cited by 52 · see citing works

Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective

Danielpour, D. (2024) · Pharmaceuticals · doi:10.3390/ph17040533 · Cited by 52 · see citing works

Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies

Ngiow, S. F., & Young, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01633 · Cited by 50 · see citing works

Exosome-mediated delivery of transforming growth factor-β receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for combination therapy of tumors

Lee, J. H., Song, J., Kim, I. G., You, G., Kim, H., Ahn, J., & Mok, H. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.01.005 · Cited by 50 · see citing works

Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy

Lee, H.-J. (2020) · Journal of Cancer Prevention · doi:10.15430/jcp.2020.25.4.213 · Cited by 49 · see citing works

Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type

Oh, J. M., Kim, S. W., Tsung, C., Kent, E. W., Jain, A., Ruff, S. M., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571731 · Cited by 49 · see citing works

Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma

Benboubker, V., Boivin, F., Dalle, S., & Caramel, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.873116 · Cited by 47 · see citing works

Immunotherapy resistance in solid tumors: mechanisms and potential solutions

Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 47 · see citing works

Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discoveryPreprint

Cuccarese, M. F., Earnshaw, B. A., Heiser, K., Fogelson, B., Davis, C. T., McLean, P., Gordon, H. B., Skelly, K.-R., Weathersby, F. L., Rodic, V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.02.233064 · Cited by 47 · see citing works

TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy

Hamon, P., de Thoré, M. G., Classe, M., Signolle, N., Liu, W., Bawa, O., Meziani, L., Clémenson, C., Milliat, F., Deutsch, É., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003519 · Cited by 46 · see citing works

The Love-Hate Relationship Between TGF-β Signaling and the Immune System During Development and Tumorigenesis

Chen, B., Mu, C., Zhang, Z., He, X., & Liu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.891268 · Cited by 46 · see citing works

Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma

Zhang, G., Chen, X., Fang, J., Tai, P., Chen, A., & Cao, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954440 · Cited by 45 · see citing works

Rebalancing TGFβ1/BMP signals in exhausted T cells unlocks responsiveness to immune checkpoint blockade therapy

Saadey, A. A., Yousif, A., Osborne, N., Shahinfar, R., Chen, Y., Laster, B., Rajeev, M., Bauman, P., Webb, A., & Ghoneim, H. E. (2022) · Nature Immunology · doi:10.1038/s41590-022-01384-y · Cited by 45 · see citing works

Exploiting protease activation for therapy

Bleuez, C., Koch, W. F., Urbach, C., Hollfelder, F., & Jermutus, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.03.011 · Cited by 43 · see citing works

SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors

Liang, S., Zheng, R., Zuo, B., Li, J., Wang, Y., Han, Y., Dong, H., Zhao, X., Zhang, Y., Wang, P., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01120-y · Cited by 42 · see citing works

Therapeutic targeting of TGF ‐β in lung cancer

Aftabi, S., Behrooz, A. B., Cordani, M., Rahiman, N., Sadeghdoust, M., Aligolighasemabadi, F., Pistorius, S., Alavizadeh, S. H., Taefehshokr, N., & Ghavami, S. (2024) · FEBS Journal · doi:10.1111/febs.17234 · Cited by 42 · see citing works

Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma

Zhou, C., Lin, A., Cao, M., Ding, W., Mou, W., Guo, N., Chen, Z., Zhang, J., & Luo, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.634741 · Cited by 42 · see citing works

Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways

Yang, C., Mai, Z., Liu, C., Yin, S., Cai, Y., & Xia, C. (2022) · Molecules · doi:10.3390/molecules27113513 · Cited by 40 · see citing works

68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer

Li, K., Liu, W., Yu, H., Chen, J., Tang, W., Wang, J., Qi, M., Sun, Y., Xu, X., Zhang, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170490 · Cited by 39 · see citing works

Signaling pathways in colorectal cancer: implications for the target therapies

Song, Y., Chen, M., Wei, Y., Ma, X., & Shi, H. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00178-y · Cited by 38 · see citing works

ASCL2 induces an immune excluded microenvironment by activating cancer-associated fibroblasts in microsatellite stable colorectal cancer

Zhang, D., Ni, Q.-Q., Liang, Q.-Y., He, L.-L., Qiu, B.-W., Zhang, L.-J., Mou, T., Le, C., Huang, Y., Li, T., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02806-3 · Cited by 37 · see citing works

Resistance to immune checkpoint inhibitors in gastric cancer

Liu, K., Yuan, S., Wang, C., & Zhu, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1285343 · Cited by 36 · see citing works

The incorporation of acetylated LAP-TGF-β1 proteins into exosomes promotes TNBC cell dissemination in lung micro-metastasis

Yu, P., Han, Y., Meng, L., Tang, Z., Jin, Z., Zhang, Z., Zhou, Y., Luo, J. F., Luo, J., Han, C. Q., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01995-z · Cited by 35 · see citing works

Cancer-Associated Fibroblasts Facilitate Squamous Cell Carcinoma Lung Metastasis in Mice by Providing TGFβ-Mediated Cancer Stem Cell Niche

Shi, X., Luo, J., Weigel, K. J., Hall, S. C., Du, D., Wu, F., Rudolph, M. C., Zhou, H., Young, C. D., & Wang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.668164 · Cited by 35 · see citing works

Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma

Lucarini, V., Melaiu, O., D’Amico, S., Pastorino, F., Tempora, P., Scarsella, M., Pezzullo, M., Ninno, A. D., Doria, V., Cilli, M., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02525-9 · Cited by 35 · see citing works

Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies

Zhao, L.-P., Hu, J.-H., Hu, D., Wang, H., Huang, C.-G., Luo, R., Huang, X., Huang, X., Xie, T., & Lou, J.-S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112949 · Cited by 32 · see citing works

Autophagy orchestrates resistance in hepatocellular carcinoma cells

Seydi, H., Nouri, K., Rezaei, N., Tamimi, A., Hassan, M., Mirzaei, H., & Vosough, M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114487 · Cited by 32 · see citing works

TIM-3 Expression and M2 Polarization of Macrophages in the TGFβ-Activated Tumor Microenvironment in Colorectal Cancer

Katagata, M., Okayama, H., Nakajima, S., Saito, K., Sato, T., Sakuma, M., Fukai, S., Endo, E., Sakamoto, W., Saito, M., et al. (2023) · Cancers · doi:10.3390/cancers15204943 · Cited by 31 · see citing works

TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model

Siewe, N., & Friedman, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252620 · Cited by 31 · see citing works

A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance

Santiago-Sánchez, G. S., Fabian, K. P., & Hodge, J. W. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2308097 · Cited by 30 · see citing works

Combinatorial Immunotherapies for Metastatic Colorectal Cancer

Janssen, E., Subtil, B., Ortiz, F. D. L. J., Verheul, H. M. W., & Tauriello, D. V. F. (2020) · Cancers · doi:10.3390/cancers12071875 · Cited by 30 · see citing works

Neutrophils: Musketeers against immunotherapy

Zahid, K. R., Raza, U., Tumbath, S., Jiang, L., Xu, W., & Huang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.975981 · Cited by 30 · see citing works

TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT–Smad3–SHP1 Axis in Lung Adenocarcinoma

Ye, F., Cai, Z., Wang, B., Zeng, C., Xi, Y., Hu, S., Qu, R., Yuan, Z., Yue, J., Tian, Y., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3009 · Cited by 30 · see citing works

Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy

Chen, M., & Wang, S.-L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111717 · Cited by 29 · see citing works

An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis

Jackson, J., Streich, F. C., Pal, A., Coricor, G., Boston, C., Brueckner, C., Canonico, K., Chapron, C., Cote, S. M., Dagbay, K. B., et al. (2024) · Science Signaling · doi:10.1126/scisignal.adn6052 · Cited by 28 · see citing works

Identification of an Immune-Related Gene Signature Based on Immunogenomic Landscape Analysis to Predict the Prognosis of Adult Acute Myeloid Leukemia Patients

Zhu, R., Tao, H., Lin, W., Tang, L. V., & Hu, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.574939 · Cited by 28 · see citing works

TGFβ: Signaling Blockade for Cancer Immunotherapy

Chen, S., Mamaï, O., & Akhurst, R. J. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070620-103554 · Cited by 28 · see citing works

Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment

Hu, L., Sun, C., Yuan, K., & Yang, P. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104181 · Cited by 27 · see citing works

Simultaneous blockage of contextual TGF-β by cyto-pharmaceuticals to suppress breast cancer metastasis

Li, Y., Hu, Q., Li, W., Liu, S., Li, K., Li, X., Du, J., Yu, Z., Wang, C., & Zhang, C. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.012 · Cited by 27 · see citing works

Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers

Kyte, J. A. (2022) · Cancers · doi:10.3390/cancers14030571 · Cited by 26 · see citing works

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy

Liu, J., Tao, H., Yuan, T., Li, J., Li, J., Liang, H., Huang, Z., & Zhang, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992611 · Cited by 26 · see citing works

Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors

Welsh, B. T., Faucette, R., Bilic, S., Martin, C. J., Schürpf, T., Chen, D. J., Nicholls, S. B., Lansita, J. A., & Kalra, A. V. (2021) · International Journal of Toxicology · doi:10.1177/1091581821998945 · Cited by 26 · see citing works

Abstract 4090: Defeating primary checkpoint resistance: SRTβ1-Ab3 is a first-in-class, fully human antibody that renders resistant tumors sensitive to anti-PD-1

Schürpf, T., Martin, C. J., Littlefield, C., Chapron, C., Wawersik, S., Kalra, A. V., Simpson, A., Danehy, F. T., Boston, C., Nikiforov, A., et al. (2019) · Immunology · doi:10.1158/1538-7445.sabcs18-4090

TGFβ1-specific antibody spurs anti-tumour immunity

Cully, M. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00058-4 · Cited by 2 · see citing works

773 SOF10, selectively blocking latent TGF-β1 activation, potentiates the efficacy of checkpoint blockade therapy by modulating CAF dynamics and T cell infiltration

Sato, I., Kanamori, M., Nakagawa, K., Sun, S., Asanuma, K., Kawauchi, H., Kayukawa, Y., Matsuo, S., Shida-Kawazoe, M., Kashiwagi, D., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-sitc2024.0773 · Cited by 1 · see citing works

First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.

Yap, T. A., Barve, M. A., Gainor, J. F., Weekes, C. D., Bockorny, B., Ju, Y., Faucette, R., Bilic, S., Lee-Hoeflich, S. T., Song, G., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps3146 · Cited by 7 · see citing works